Last reviewed · How we verify
LY2922470
At a glance
| Generic name | LY2922470 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY2922470 in Healthy Participants and Participants With Diabetes (PHASE1)
- A Study of Multiple Doses of LY2922470 in Participants With Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2922470 CI brief — competitive landscape report
- LY2922470 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI